Quoin Pharmaceuticals announced plans to initiate several investigator-led clinical studies for its QRX009 topical rapamycin lotion targeting rare skin diseases including Pachyonychia Congenita, Gorlin Syndrome, and Tuberous Sclerosis Complex. The first study, led by Professor Edel O’Toole, will start in Q3 2026 focusing on Pachyonychia Congenita, a rare skin condition with no approved treatments. Quoin also aims to submit an Investigational New Drug Application to the FDA for an additional indication of QRX009 in Q3 2026. These efforts complement their ongoing late-stage programs and mark a significant step in addressing unmet medical needs in rare dermatological conditions.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
NYDIG projects Bitcoin might fall to $38,000-$39,000 by October 2026 if the current 2025-26 market decline matches the depth of the 2022 bear market. Bitcoin is currently trading near $64,500, down about 30% this year and roughly 50% below its Octobe...
PepsiCo is rated a strong buy due to its attractive combination of dividend yield, earnings growth, and undervaluation. The company is projected to achieve a forward compound annual growth rate (CAGR) between 13.7% and 18.2%, supported by dividend in...
The XRP Ledger (XRPL) has exceeded 8 million activated accounts, marking significant growth driven by institutional interest and AI integration. Originally built for fast cross-border payments, XRPL now supports tokenization of real-world assets, dec...
Ora Banda Mining Ltd (ASX:OBM) melaporkan rekor produksi emas pada kuartal Juni 2026, mencapai 39.552 ounce, sehingga total produksi setahun penuh menjadi 140.949 ounce. Perusahaan mengakhiri Juni dengan kas A$267,7 juta dan total likuiditas A$468 ju...
